Market Overview

UPDATE: Deutsche Bank Upgrades Johnson & Johnson to Buy on Improving Trends

Related JNJ
The 4 Companies Teaming Up For A New Tool To Fight Cancer
#PreMarket Primer: Friday, August 22: Draghi, Yellen Set To Speak At Jackson Hole
Johnson & Johnson CEO: No Plans to Leave U.S. (Fox Business)

Deutsche Bank raised its rating on Johnson & Johnson (NYSE: JNJ) from Hold to Buy and increased its price target from $75 to $82.

Deutsche Bank commented, "For the past several years, JNJ has weathered through patent expirations, a general slowdown in utilization trends, and challenges with its OTC businesses. As we look ahead to 2013, we believe JNJ will see improving trends. We expect recent and new drugs to continue to drive pharma sales. A slight improvement in utilization and new products should benefit MD&D. For Consumer, J&J should continue to work through the McNeil Consent Decree and return products to market. Given these improving trends and the benefits of diversification, we believe JNJ deserves a premium to its peers."

Johnson & Johnson closed at $70.74 on Thursday.

Posted-In: Deutsche BankAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters